The number of osteonecrosis related medications of the jaw is constantly increasing, as is apparent from the many molecular target and immunological drugs in the last years introduced in the cancer treatment. In addition to bisphosphonates and denosumab, recently cases due to bevacizumab, sunitinib and ipilimumab have been described.
No takes yet. Share an insight, caveat, or question.
AF et al. (2017) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: